Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RMTI 
Rockwell Medical Inc (RMTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: RMTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.89% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.25M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 2 | Beta 1.73 | 52 Weeks Range 0.78 - 5.15 | Updated Date 10/13/2025 |
52 Weeks Range 0.78 - 5.15 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -2.39% | Operating Margin (TTM) -8.39% |
Management Effectiveness
Return on Assets (TTM) -1.53% | Return on Equity (TTM) -7.79% |
Valuation
Trailing PE - | Forward PE 59.17 | Enterprise Value 37245725 | Price to Sales(TTM) 0.45 |
Enterprise Value 37245725 | Price to Sales(TTM) 0.45 | ||
Enterprise Value to Revenue 0.42 | Enterprise Value to EBITDA 30.21 | Shares Outstanding 34430352 | Shares Floating 28141993 |
Shares Outstanding 34430352 | Shares Floating 28141993 | ||
Percent Insiders 14.07 | Percent Institutions 17.19 |
Upturn AI SWOT
Rockwell Medical Inc
Company Overview
History and Background
Rockwell Medical Inc. was founded in 1995. It is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative therapies and services.
Core Business Areas
- Drug Products: Focuses on developing and commercializing drug products for patients with kidney disease. The company's main products are Triferic AVNU for hemodialysis and Triferic Dialysate for peritoneal dialysis, which are iron replacement therapies that maintain hemoglobin levels and reduce the need for erythropoiesis-stimulating agents (ESAs).
- Equipment and Services: Previously offered dialysis concentrates, dialysis equipment, and services; however, the company divested its dialysis business in 2023.
Leadership and Structure
Mark Strobeck, Ph.D. is the President and CEO. The company is structured with various departments including research & development, clinical operations, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Triferic AVNU: Triferic AVNU is an FDA-approved intravenous iron maintenance therapy indicated for the treatment of iron deficiency in adult patients with hemodialysis-dependent chronic kidney disease (CKD). While specific market share data is dynamic, Triferic competes with traditional IV iron products. Competitors include Vifor Pharma, AMAG Pharmaceuticals (now part of Covis Pharma), and Akebia Therapeutics. Revenue data specific to Triferic AVNU is not publicly available on a product-by-product basis but is incorporated into Rockwell Medical's overall pharmaceutical sales.
- Triferic Dialysate: Triferic Dialysate is an FDA-approved dialysate solution for use in peritoneal dialysis, indicated for iron maintenance and hemoglobin maintenance in adult patients with peritoneal dialysis-dependent chronic kidney disease (CKD). Competitors include Baxter International and Fresenius Medical Care who provide solutions for peritoneal dialysis.
Market Dynamics
Industry Overview
The renal disease market is driven by the increasing prevalence of diabetes and hypertension, major causes of kidney failure. This market includes pharmaceuticals, dialysis equipment, and services. Demand is high due to the chronic nature of the disease and an aging population.
Positioning
Rockwell Medical is positioned as a specialized pharmaceutical company focused on innovative iron therapies to improve outcomes for dialysis patients. Their key differentiator is Triferic, a product designed to deliver iron while minimizing ESA use and associated risks. They position themselves as a leader in iron maintenance therapy.
Total Addressable Market (TAM)
The global dialysis market is estimated at over $90 billion. Rockwell Medical, with Triferic products, targets the iron management portion of this market, representing a portion of this TAM. The peritoneal dialysis market, in particular, is expected to grow which gives Rockwell significant opportunity.
Upturn SWOT Analysis
Strengths
- FDA-approved, differentiated Triferic product line
- Specialized expertise in iron management for dialysis patients
- Focus on addressing a significant unmet need in the renal disease market
- Potential for expansion into new indications or delivery methods
Weaknesses
- Reliance on a limited product portfolio
- Small market capitalization may limit access to capital
- Dependence on regulatory approvals and reimbursement
- Historically unprofitable
Opportunities
- Expanding Triferic into new markets or geographies
- Developing new formulations or delivery methods for Triferic
- Acquiring or partnering with other companies in the renal disease space
- Increasing awareness and adoption of Triferic among healthcare providers
Threats
- Competition from established dialysis providers and pharmaceutical companies
- Changes in reimbursement policies or regulatory requirements
- Generic entry of Triferic
- Clinical trial failures or adverse events
Competitors and Market Share
Key Competitors
- BMY
- VIF.SW
- BAX
- FMS
Competitive Landscape
Rockwell Medical faces competition from larger, more established companies in both the dialysis and pharmaceutical markets. Its advantage lies in its specialized focus and potentially differentiated product.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth was tied to dialysis products and services, but with the divestiture, future growth depends primarily on Triferic products. Growth has been hindered by financial challenges.
Future Projections: Future growth is expected to depend on increasing sales of Triferic products. Analyst estimates are not readily available, but company management aims to achieve profitability through increased market penetration and cost management.
Recent Initiatives: The divestiture of the dialysis business to Baxter International in 2023. Focus on the Triferic product line.
Summary
Rockwell Medical is a biopharmaceutical company navigating a complex transition after selling its dialysis business. The company's success hinges on the growth of Triferic and its ability to effectively compete against larger players in the renal disease space. It has a product with a differentiated mechanism that offers several advantages. While the company has a unique product and a market need, it should monitor and watch out for changes in the industry, new entrants into the market and pricing pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Rockwell Medical Inc. SEC Filings (10-K, 10-Q)
- Company Press Releases
- Investor Presentations
- Third-party Market Research Reports
- FDA Website
- Company Website
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice and should not be used as the sole basis for investment decisions. Market share data is approximate and may vary based on source and methodology. All financial data is based on publicly reported figures and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rockwell Medical Inc
Exchange NASDAQ | Headquaters Wixom, MI, United States | ||
IPO Launch date 1998-01-27 | President, CEO & Director Dr. Mark Strobeck Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 244 | Website https://www.rockwellmed.com |
Full time employees 244 | Website https://www.rockwellmed.com | ||
Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. Its hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics, including dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.